Compare Enphase Energy Inc (ENPH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs TG Therapeutics Inc — how do they compare? Enphase Energy Inc trades at $32.7 (market cap $4.35B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and TG Therapeutics Inc for 16 Days on average.
| ENPH | TGTX | |
|---|---|---|
Market Cap | $4.35B | $8.16B |
Volume | 5,068,595 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $72.33 | $59.06 |
52-Week Low | $26.12 | $26.94 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $3.99B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.81, down 2.06% on the day, with a bearish technical signal from moving averages and mixed recent earnings. The company reported revenue of $1.47B and net income of $172.13M for 2025, with a P/E ratio of 32.58. Recent news highlights product approvals and manufacturing milestones for AI data center power solutions, though the solar sector faces headwinds from high borrowing costs.
The outlook is cautious; while analyst consensus is a Buy with a $42.90 price target, near-term risks include sector volatility and recent earnings misses. Long-term opportunities hinge on execution in the energy technology and AI infrastructure markets, but investors should weigh competitive pressures and macroeconomic factors affecting solar project financing.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
